Mechanical Circulatory Support for the Failing Heart: Continuous-Flow Left Ventricular Assist Devices Article

PMID: 27660575 Web of Science: 000389241000016

Cited authors

  • Englert, Joseph A. R., III; Davis, Jennifer A.; Krim, Selim R.


  • Background: Heart transplantation remains the definitive therapy for patients with advanced heart failure; however, owing to limited donor organ availability and long wait times, continuous-flow left ventricular assist devices (LVADs) have become standard therapy.; Methods: This review summarizes the history, progression, function, and basic management of LVADs. Additionally, we provide some clinical pearls and important caveats for managing this unique patient population.; Results: Currently, the most common LVADs being implanted in the United States are second-and third-generation devices, the HeartMate II (Thoratec Corp., St. Jude Medical) and the HeartWare HVAD (HeartWare International, Inc.). A newer third-generation pump, the HeartMate III (Thoratec Corp., St. Jude Medical), is designed to create an artificial pulse and is currently under investigation in the United States.; Conclusion: LVAD use is promising, will continue to grow, and has become standard therapy for advanced heart failure as a bridge to recovery, as destination therapy, and as a bridge to transplantation.

Publication date

  • 2016

Published in

International Standard Serial Number (ISSN)

  • 1524-5012

Start page

  • 263

End page

  • 269


  • 16


  • 3